论文部分内容阅读
目的 分析23G微创玻璃体手术治疗永存原始玻璃体增生症的临床效果.方法 永存原始玻璃体增生症患儿19名(19眼),应用23G微创玻璃体手术系统行晶状体摘出联合玻璃体切除术,其中15例一期植入人工晶状体.术后随访6～36个月.观察术中、术后并发症,视力恢复及结构恢复情况.结果 术中及术后均无明显的并发症;至随访期末,17眼(89.47％)视力有不同程度的提高,19例均获得了一定的视力,未发生因病情发展或因并发症而导致二次手术者.其中视力无变化者2眼,术中检查发现存在视网膜发育异常.结论 应用23G微创玻璃体手术治疗永存原始玻璃体增生症是一种安全有效的方法,并发症少,术后反应轻,尽早手术可保护有用视力,防止并发症发生.“,”Objective To analyze the clinical effect of 23G micro-invasive vitreous surgery in treatment of persistent hyperplasia of primary vitreous (PHPV).Methods A retrospective study of 19 eyes of 19 children with PHPV treated with 23G micro-invasive vitreous surgery,extraction of the crystalline lens combined with vitrectomy included 15 cases with intraocular lens implantation.They were followed up for 6 to 36 months.The intraoperative and postoperative complications and visual acuity were analysed.Results There was no significant intraoperative or postoperative complication at the end of the follow-up.The vision were improved in 17 eyes (89.47％) at varying degrees.All 19 children acquired certain vision.No case needed secondary surgery due to the disease progression or complications.Among them,the visual acuity remained unchanged in 2 cases who had retinal dysplasia discovered during the surgery.Conclusion 23G micro-invasive vitreous surgery for PHPV is a safe and effective method which has few complications and mild postoperative reaction.Early surgery may be useful to protect eyesight and prevent complications.